NewAmsterdam Pharma announces additional data from BROADWAY, TANDEM studies

NewAmsterdam Pharma (NAMS) announced additional data from the BROADWAY and TANDEM pivotal Phase 3 studies were presented as late-breaking oral presentations at the European Atherosclerosis Society Congress, EAS, 2025 and simultaneously published in The New England Journal of Medicine and The Lancet. Key previously-reported findings from the BROADWAY clinical trial evaluating obicetrapib in patients with atherosclerotic cardiovascular disease and/or heterozygous familial hypercholesterolemia: Achieved primary endpoint showing a 33% reduction compared to placebo in LDL-C on top of maximally tolerated lipid modifying therapies at day 84. In an exploratory safety analysis we observed a 21% relative reduction in the exploratory endpoint of major adverse cardiovascular events, including coronary heart disease death, non-fatal myocardial infarction, non-fatal stroke, and coronary revascularization. Observed improvements across key biomarkers, including high-density lipoprotein cholesterol, non-HDL-C, lipoprotein(a), apolipoprotein B, and Apolipoprotein A1, were consistent with prior clinical trials. Obicetrapib was observed to be well-tolerated, with a safety profile that was comparable to placebo, consistent with all clinical trials conducted to date.